Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 45%
Hold 36%
Sell 9%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is a promising company in a growing market, with a focus on developing and selling innovative surgical robotics systems for urology. The company has faced some challenges in recent quarters, including slower procedure growth and restructuring under new leadership. However, it has outlined promising sales initiatives that could increase utilization and drive higher profitability, and the company's financials are still strong with a potential for future growth. While there are some risks to consider, such as competitive pressures and uncertainty in utilization and procedure trends, we believe the stock has the potential for significant upside in the long term.

Bears say

PROCEPT BioRobotics is facing multiple headwinds including restructuring of their sales force and likely decrease in demand due to alternative surgical and therapeutic options for BPH treatment. This is evident in their lower than expected handpiece sales and procedure growth, which has led to a decrease in their revenue forecast for 2026-2027. Furthermore, the increase in reimbursement for prostatic artery embolization (PAE) could lead to further shift away from Aquablation therapy, limiting growth prospects for the company. Additionally, potential competition from other surgical systems and pricing pressure could also have a negative impact on sales. As a result, we have a negative outlook on PROCEPT BioRobotics' stock.

PRCT has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Hold based on their latest research and market trends.

According to 11 analysts, PRCT has a Hold consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.